logo.jpg
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
17 sept. 2021 08h00 HE | ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021         First EVICTION data from checkpoint inhibitor-refractory solid tumor...
22157.jpg
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
19 avr. 2021 08h18 HE | Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...
22157.jpg
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
29 mars 2021 06h53 HE | Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
22157.jpg
United States Cancer Biosimilar Market Report 2021: $15 Billion Opportunity, Drug Dosage, Price & Clinical Trials Insight to 2026
19 mars 2021 06h43 HE | Research and Markets
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's...
new logo.jpg
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16 mars 2021 08h00 HE | Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
new logo.jpg
Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE | Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
22157.jpg
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
17 févr. 2021 08h38 HE | Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...
22157.jpg
Global Checkpoint Inhibitors Market Report 2020-2030: COVID-19 Growth and Changes
22 déc. 2020 05h23 HE | Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Immune Checkpoint Inhibitors Market, 2025
30 oct. 2020 04h53 HE | Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The...
Vaccinex logo
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
17 sept. 2020 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...